Medicines price transparency: Ground still left to cover

Parts of this blog were previously published in the Lancet Regional Health Europe Secret medicines prices are hotly debated as European health systems struggle to...

Something is going terribly wrong with the EU Compulsory Licensing Regulation

This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...

According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...

Why The Request By Least Developed Countries For An Extension Of The Transitional Period...

On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...

Uganda tells ARIPO: No more patents for pharmaceuticals

Uganda has notified the African Regional Intellectual Property Organisation (ARIPO) that pharmaceutical inventions are not eligible for patentability in the country, Managing IP reported. With...

Human Rights Watch: All governments should endorse the WHO C-TAP Solidarity Call to Action

As the race towards a Covid-19 vaccine continues – with 11 leading candidates in phase 3 clinical trials, 14 more in phase 2 and...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Covid-19 intellectual property pool gaining support

While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...

Wrapping Up 2017 – some noteworthy medicines law and policy events.

2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...